BriaCell Therapeutics Corp. BCTX
Last close
3.57
2026-09-04
Market cap
$31.1M
2026-04-30 share count
52-week range
2.60 - 14.68
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-62.19
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $21.3M | $27.2M | $15.3M | $8.0M | $2.0M | — | — | — |
| SG&A | $5.9M | $6.2M | $7.9M | $7.3M | $5.0M | — | — | — |
| Total operating expenses | $27.2M | $33.3M | $23.3M | — | — | — | — | — |
| Operating income | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M | -$3.9M | — | — |
| Interest expense | $37.0K | — | — | $979 | $78.6K | — | — | — |
| Pre-tax income | $26.6M | $4.9M | $20.3M | -$26.8M | -$13.8M | — | — | — |
| Income tax | — | — | — | $0 | $0 | — | — | — |
| Net income | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M | -$4.0M | -$4.7M | — |
| EPS, basic | -62.19 | -43.68 | -1.30 | -1.73 | -3.06 | — | — | — |
| EPS, diluted | -62.19 | -43.68 | -1.30 | -1.73 | — | — | — | — |
| Shares, diluted (wtd. avg.) | $423.1K | $109.7K | $15.6M | $15.5M | $4.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.5M | $862.1K | $21.3M | $41.0M | $57.3M | — | — | — |
| Short-term investments | $7.4M | — | — | — | — | — | — | — |
| Receivables | — | — | $18.9K | $24.1K | $12.6K | — | — | — |
| Total current assets | $19.9M | $3.7M | $26.9M | $42.3M | $57.8M | — | — | — |
| Property, plant and equipment | $296.8K | $388.2K | $2.5K | $2.5K | — | — | — | — |
| Other intangibles | $184.5K | $199.8K | $215.1K | $230.3K | $245.6K | — | — | — |
| Total assets | $21.6M | $5.9M | $27.2M | $42.6M | $58.0M | $522.3K | $444.7K | — |
| Total current liabilities | $4.0M | $7.5M | $1.8M | $941.1K | $556.8K | — | — | — |
| Retained earnings | -$111.8M | -$85.4M | -$80.7M | -$60.3M | -$29.1M | — | — | — |
| Total equity | $17.3M | -$2.7M | -$3.8M | $10.3M | $27.7M | -$2.7M | -$688.7K | $1.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M | — | — | — |
| Depreciation and amortisation | $91.4K | $68.6K | — | $15.3K | $15.3K | — | — | — |
| Stock-based compensation | $776.9K | $1.8M | $2.2M | $3.1M | $2.0M | — | — | — |
| Capital expenditure | — | $456.8K | — | — | — | — | — | — |
| Investing cash flow | -$7.6M | -$681.8K | — | — | — | — | — | — |
| Financing cash flow | $45.4M | $4.4M | $4.0M | -$3.7M | $65.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-25-018212.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |